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Antibiotics-All-Purpose Agents
One of the greatest discoveries in medicine was the observation by Dr. Alexander
Fleming that the fungus, Penicillium notatum, excreted a substance, subsequently
named penicillin, that inhibited growth of bacteria. This discovery was particularly
fortuitous because of penicillin’s low toxicity to human cells. Penicillin is an ex-
emplary antibiotic because its primary mechanism of action is to interfere with or
inhibit the synthesis of the bacterial cell wall. The human cell does not possess a
cell wall and therefore is not subject to action of penicillin. However, penicillin
should not be misconstrued as being totally without potential harm for humans;
e.g., anaphylaxis.
Since Fleming’s discovery, many antibiotics have been developed that do not
have a highly specialized mechanism of action that is unique to the bacterial cell.
Many of these newer agents have the potential to interact with human cellular
function. Unfortunately, these interactions are not uncovered until after millions of
doses of the antibiotic have been administered.
Administering antibiotics in the absence of true bacterial infection has the
potential for doing more harm than good. It is important to understand that anti-
biotics may result in harm to the patient and may select for resistant bacterial
strains. These two facts are extremely important for the physician to bear in mind
when considering the administration of antibiotics to patients.
Antibiotics are not antipyretic agents and should not be given to patients only
because their body temperature is increased. This is commonly done in patients
with fever and symptoms of pharyngitis. Often the patient is requesting antibiot-
ics, and the physician agrees because he or she does not want to anger the patient.
In addition, the physician often feels that the antibiotic is innocuous and cannot
cause harm to the patient. Another instance when antibiotics are prescribed indis-
criminately is in postoperative fever. The typical response to a patient who has had
a hysterectomy or cesarean section and develops a fever is to give antibiotics
without a thorough evaluation. When the patient responds, e.g., becomes afebrile
in 24 hours, the physician feels justified in having administered antibiotics.
Antibiotics are not tocolytic agents. However, it is common practice to admin-
ister antibiotics to pregnant women in preterm labor in the belief that antibiotics
can increase the latent phase and therefore allow the administration of steroids.
The selection of resistant bacterial strains is beginning to surface in our spe-
cialty This has been demonstrated by the selection of Enterococcus faecalis in in-
dividuals receiving cephalosporin prophylaxis. It is also seen in women receiving
ampicillin "prophylaxis" for the prevention of the prenatal transmission of Strep-
tococcus aga]actiae.
One other area of concern is in the treatment of bacterial vaginosis, not an
infection but a disruption in the vaginal ecosystem. The two most common treat-
ment regimens, clindamycin vaginal cream (Cleocin) and metronidazole adminis-
tered either intravaginally or orally, are not particularly successful. They result in
either multiple exposures to the antibiotic or the empiric use of other antimicrobial
agents. Once again, the selective pressures exerted on the bacterial microflora of
the genital tract as well as other ecosystems of the body are immense.
EditorialOne other consideration is the effect of all these antibiotics on the environment.
There is tremendous pressure on the environment secondary to the high volume
of antibiotics used to treat humans and animals.
The infectious disease societies, IDSOG and IIDSOG-USA, should assume the
responsibility of educating physicians and other healthcare providers in the proper
use of antibiotics, as well as in the consequences of indiscriminate and inappro-
priate use of antimicrobial agents. The societies should not endorse any antimi-
crobial agent for a specific use unless there is sufficient data to support this
indication.
There must also be sufficient safety data. The societies must be emphatic that
if there are no data to support use of a particular drug in pregnant women it should
be withheld from these individuals as well as from breastfeeding women.
The infectious disease societies should also assist the pharmaceutical industry
in the development of these agents and not be influenced by the opportunity to
gain financial support for their research The pharmaceutical industry has been a
friend to medicine, supporting research and education. The societies must, in turn,
be a true friend to the pharmaceutical industry by being honest and helping to
guide them through product development.
Although profit is a motivator, short-term profit can turn out to be long-term loss
if unexpected adversity results from the administration of an antimicrobial agent.
The academic investigator, whether or not performing clinical or basic science
research supported by the pharmaceutical industry, must remain neutral with
regard to the industry. The investigator must also remain distanced from the
industry and, thereby, unencumbered in rendering data, opinions, and recommen-
dations.
Infectious diseases remain a serious threat to the well-being of our patients. The
members of IDSOG and IIDSOG-USA have a responsibility to our patients to
bring forth not only new and better antimicrobials, but also agents that truly are an
improvement over existing ones. The societies should also help to ensure that
these agents are safe. Although our role in preventing selection of resistant bac-
teria, fungi, and parasites may seem minor, it is a significant one.
Sebastian Faro, MD, PhD
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